Dow Jones

40,211.72

0.00%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
23/04/2015	06:30	Business Wire	Acceleron Pharma to Present at Upcoming Investor Conferences in May	NASDAQ:XLRN	Acceleron Pharma Inc
21/04/2015	15:46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
21/04/2015	09:51	The Motley Fool	3 Bursting Biotech Stocks -- 1 To Buy	NASDAQ:XLRN	Acceleron Pharma Inc
17/04/2015	15:43	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XLRN	Acceleron Pharma Inc
17/04/2015	15:42	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XLRN	Acceleron Pharma Inc
10/04/2015	15:19	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:XLRN	Acceleron Pharma Inc
08/04/2015	16:10	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:XLRN	Acceleron Pharma Inc
07/04/2015	06:00	Business Wire	Acceleron Announces Oral Presentations of Luspatercept & Sotatercept Data at the 13th International Symposium on Myelodysplas...	NASDAQ:XLRN	Acceleron Pharma Inc
06/04/2015	06:00	Business Wire	Acceleron Pharma Appoints Dr. Francois Nader as Chairman of its Board of Directors	NASDAQ:XLRN	Acceleron Pharma Inc
06/03/2015	08:17	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
06/03/2015	07:00	Business Wire	Acceleron Pharma Announces Executive Appointments and Promotions	NASDAQ:XLRN	Acceleron Pharma Inc
02/03/2015	10:56	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:XLRN	Acceleron Pharma Inc
02/03/2015	06:00	Business Wire	Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results	NASDAQ:XLRN	Acceleron Pharma Inc
28/02/2015	09:00	Business Wire	Acceleron Presents Encouraging Response Rates & Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma...	NASDAQ:XLRN	Acceleron Pharma Inc
26/02/2015	06:00	Business Wire	Acceleron Pharma to Present at Upcoming Investor Conferences in March	NASDAQ:XLRN	Acceleron Pharma Inc
24/02/2015	06:00	Business Wire	Acceleron Pharma to Host Fourth Quarter and Year Ended 2014 Financial Results Conference Call and Webcast on March 2, 2015	NASDAQ:XLRN	Acceleron Pharma Inc
19/02/2015	06:00	Business Wire	Acceleron to Present New Dalantercept Clinical Data at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Ca...	NASDAQ:XLRN	Acceleron Pharma Inc
17/02/2015	15:18	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XLRN	Acceleron Pharma Inc
17/02/2015	15:05	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:XLRN	Acceleron Pharma Inc
06/02/2015	16:25	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XLRN	Acceleron Pharma Inc
28/01/2015	06:00	Business Wire	Acceleron Pharma to Present at Upcoming Investor Conferences in February	NASDAQ:XLRN	Acceleron Pharma Inc
12/01/2015	06:00	Business Wire	Acceleron Pharma Outlines Corporate Objectives for 2015	NASDAQ:XLRN	Acceleron Pharma Inc
15/12/2014	07:00	Business Wire	Acceleron Pharma Added to NASDAQ Biotechnology Index	NASDAQ:XLRN	Acceleron Pharma Inc
12/12/2014	15:52	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (3/a)	NASDAQ:XLRN	Acceleron Pharma Inc
12/12/2014	15:36	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
12/12/2014	06:30	Business Wire	Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors	NASDAQ:XLRN	Acceleron Pharma Inc
10/12/2014	06:30	Business Wire	Luspatercept Data on Myelodysplastic Syndromes Selected for “Best of ASH” by the American Society of Hematology	NASDAQ:XLRN	Acceleron Pharma Inc
08/12/2014	13:00	Business Wire	New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition	NASDAQ:XLRN	Acceleron Pharma Inc
07/12/2014	11:00	Business Wire	New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (A...	NASDAQ:XLRN	Acceleron Pharma Inc
24/11/2014	06:30	Business Wire	Acceleron Pharma to Present at Upcoming Investor Conferences in December	NASDAQ:XLRN	Acceleron Pharma Inc